The impact of left ventricular hypertrophy (LVH) on survival among patients with established coronary artery disease (CAD) is not well understood. We sought to evaluate the effect of LVH on the survival of patients with CAD following percutaneous coronary intervention (PCI). Three hospitals in New York City contributed prospectively defined data on 4284 consecutive patients undergoing PCI. Allcause mortality at a mean follow-up of three years was the primary endpoint. LVH was present in 383 patients (8.9%). LVH patients had a greater prevalence of hypertension (88% vs. 68%, p<0.001), vascular disease (21% vs. 6.6%, p=0.001), and prior heart failure (10% vs. 5.5%, p<0.001). LVH patients presented less often with one-vessel disease (38% vs. 50%, p=0.040) and more often with two- (34% vs. 29%, p=0.014) or three-vessel (22% vs. 18%, p=0.044) disease. Ejection fractions and angiographic success were similar in both groups. In-hospital mortality did not differ between groups. At three-year follow-up, the survival rate for patients with LVH was 86% vs. 91% in patients without LVH (log-rank p=0.001). However, after adjustment for differences in baseline characteristics using Cox proportional hazards analysis, LVH was found not to be an independent predictor of mortality (hazard ratio, 0.93; 95% confidence interval, 0.68-1.28; p=0.67). We conclude that LVH at the time of PCI is not independently associated with an increase in the hazard of death at three years.
Angioplasty, stent, left ventricular hypertrophy, survival.
David L. Brown, Division of Cardiovascular Medicine, Stony Brook University Health Sciences Center T 16-080, Stony Brook, NY 11794-8171, USA. E-mail: david.brown@stonybrook. edu
Share this Article
Related Content In Interventional Cardiology
Foreword – Heart International. 2020;14(2):66
Welcome to the latest edition of Heart International. I would like to begin by paying tribute to all the victims of the coronavirus pandemic. I know of very few people who have not lost a family member, friend, colleague or a neighbour with COVID-19. Such deaths are not simply statistics, for behind each death is a […]
A Review of Bleeding Risk with Impella-supported High-risk Percutaneous Coronary Intervention
Heart International. 2020;14(2):92-99 DOI: https://doi.org/10.17925/HI.2020.14.2.92
Percutaneous coronary intervention (PCI) has evolved over recent years, with increasingly more complex, high-risk procedures being performed, including in patients with multivessel coronary artery disease with or without left main disease, often complicated by severe left ventricular (LV) dysfunction.1 In addition, decisions about coronary bypass surgery or PCI often focus not only on coronary anatomy, […]
Summary of Practice Considerations for Percutaneous Coronary Intervention of Left Main Bifurcation Disease
Heart International. 2020;14(2):69-72 DOI: https://doi.org/10.17925/HI.2020.14.2.69
Technical approaches to left main (LM) revascularisation by percutaneous techniques continues to be in evolution. This manuscript will attempt to summarise the current best practices for LM percutaneous coronary intervention (PCI). Following a clinical decision for PCI of left main bifurcation (LMB) stenosis, based on angiographic, imaging and functional severity, and supported by current guidelines […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!